Finally, important medication information including lipid-lowering agents, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists, etc., which can reduce the CAD risk, was not available for the study. Here, SLC5A2 is linked to coronary artery disorder.